2023
Associations Between Repeated Measures of Urinary Phthalate Metabolites With Hormones and Timing of Natural Menopause
Ding N, Zheutlin E, Harlow S, Randolph J, Mukherjee B, Park S. Associations Between Repeated Measures of Urinary Phthalate Metabolites With Hormones and Timing of Natural Menopause. Journal Of The Endocrine Society 2023, 7: bvad024. PMID: 36846211, PMCID: PMC9945847, DOI: 10.1210/jendso/bvad024.Peer-Reviewed Original ResearchSex hormone-binding globulinFollicle-stimulating hormoneAnti-Mullerian hormoneUrinary phthalate metabolitesTiming of natural menopausePhthalate metabolitesNatural menopauseExposure to phthalatesMeasures of urinary phthalate metabolitesAssociations of phthalate metabolitesHazard ratioAssociations of urinary phthalate metabolitesSerum concentrations of estradiolHormone-binding globulinCox proportional-hazards modelStudy of Women's HealthConcentrations of estradiolCalculate hazard ratiosProportional-hazards modelStatistically significant associationCirculating levels of testosteroneLevels of testosteroneHormone therapyOvarian reserveMidlife women
2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported dataUrinary metals and metal mixtures and timing of natural menopause in midlife women: The Study of Women’s Health Across the Nation
Wang X, Ding N, Harlow S, Randolph J, Mukherjee B, Gold E, Park S. Urinary metals and metal mixtures and timing of natural menopause in midlife women: The Study of Women’s Health Across the Nation. Environment International 2021, 157: 106781. PMID: 34311223, PMCID: PMC8490279, DOI: 10.1016/j.envint.2021.106781.Peer-Reviewed Original ResearchConceptsMetal mixturesMetal concentrationsTiming of natural menopauseCox proportional hazards modelsNatural menopauseStudy of Women's HealthProportional hazards modelHazard ratioEnvironmental risk scoreLowest quartileIndividual metal concentrationsExposure to metalsUrinary metal concentrationsHazards modelMedian follow-upMonths of amenorrheaWomen's HealthAssociated with earlier natural menopauseEarly natural menopauseUrinary metalsNation Multi-Pollutant StudyBleeding episodesHormone therapyPremenopausal womenMedian age
2020
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Consortium F. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology 2020, 158: 702-709. PMID: 32641237, PMCID: PMC7487048, DOI: 10.1016/j.ygyno.2020.06.481.Peer-Reviewed Original ResearchConceptsMenopausal hormone therapyOvarian cancer survivalMHT useResidual diseaseHormone therapyCancer survivalOvarian cancerHigh-grade serous carcinomaMacroscopic residual diseaseHormone therapy useFavorable prognostic factorPost-menopausal womenOvarian Cancer Association ConsortiumProportional hazards modelRecency of useImproved survivalPrognostic factorsTherapy useSerous carcinomaOvarian carcinomaHazards modelSmall studyAdvanced stageLarger studyLogistic regression